-
How are the World Cup favourites shaping up?
-
Taiwan leader says 'foreign forces' cannot decide island's future
-
Knicks rally to stun Cavs in overtime in NBA Eastern Conference finals opener
-
Pressure mounts at United Nations for climate change 'lifeline'
-
Cubans want change, but not at gunpoint
-
Asia stocks slide on inflation fears as yields surge
-
Putin, Xi to underscore alliance strength after Trump visit
-
Help wanted: Australian conservation group seeks new koala rescue dog
-
Musk's empire as SpaceX counts down to Wall Street liftoff
-
SpaceX's IPO moonshot draws some doubters on Wall Street
-
Under Trump pressure, EU agrees to implement US trade pact
-
Republican who stood up to Trump defeated in Kentucky primary
-
Acting US attorney general defends fund for prosecuted Trump allies
-
Mavericks part ways with head coach Kidd
-
Shock and bafflement at San Diego mosque where three were killed
-
US enforces law to crack down on sexual deepfakes
-
Arsenal crowned Premier League champions after Man City draw
-
New York art auctions roar back with blockbuster sales
-
US says held talks with Cuba on $100 mln offer
-
Chelsea beat Spurs to leave rivals in 'embarrassing' relegation danger
-
Google wants its search bar to act on your behalf in AI revamp
-
Taiwan author wins International Booker for 'slyly sophisticated' novel
-
Iran 'very confident' about World Cup protocols: federation vice-president
-
Google unveils smart glasses, taking on Meta
-
Guardiola swerves Man City exit talk as title hopes ended
-
Chiefs' Rice jailed for probation violation
-
Five factors in Arsenal's Premier League title triumph
-
Mikel Arteta: Pep protege to Premier League winner
-
How Arsenal banished 'nearly men' tag to end 22-year title wait
-
Arsenal win Premier League after Man City held by Bournemouth
-
From graduation boos to voter unease: AI anxiety grows in the US
-
Lost in Trump's climate boast: best-case scenario abandoned
-
Hantavirus cruise operator says ship not source of outbreak
-
Trump shows off ballroom site with 'drone empire' planned for roof
-
Rubio to attend NATO talks, pay first visit to India
-
Under Trump pressure, EU seeks deal to end trade standoff
-
Airbus seeks to cut peripheral expenses due to Mideast war
-
France encourages women to report rape in probes of star Bruel
-
Guardiola silent on Man City exit reports
-
Argentine researchers collect rodents for hantavirus tests
-
Iran talks making 'good progress': US VP Vance
-
Teen wonder Sooryavanshi's slams 93 to edge Rajasthan closer to IPL play-offs
-
Norway reports Europe's first case of bird flu in a polar bear
-
Italy's Ganna wins time-trial in Giro shake-up
-
EU vows help for farmers hit by Iran war fertiliser price hikes
-
Emery focused on Villa glory, not crown of Europa League 'king'
-
French govt slams 'disproportionate' Canal+ riposte to anti-Bollore petition
-
US, Iran trade threats but Trump says Tehran wants peace deal
-
Russia's Zvyagintsev sets film amid 'disaster' Ukraine war
-
UK trade minister hopes Britain will rejoin EU 'in my lifetime'
Biden calls for lower prices of Ozempic, similar drugs
US President Joe Biden on Tuesday called on pharmaceutical giants Novo Nordisk and Eli Lilly to lower prices for diabetes and weight loss drugs such as Ozempic, saying firms must stop "ripping off the American people."
In an article written with Senator Bernie Sanders, Biden said US patients pay several times more than in Canada, Germany and Denmark for Nordisk's diabetes drugs Ozempic and Wegovy, which can also be used for weight loss.
One-month supply of Ozempic in the United States last year was $936, compared to $169 in Canada and $103 in Germany, according to one study.
Eli Lilly was also charging "unconscionably high prices" for Mounjaro, a drug similar to Ozempic.
"Why should people in Burlington, Vermont, pay so much more than people in Copenhagen or Berlin for the same drug?" wrote Biden and Sanders, who chairs the Senate healthcare committee.
Such "price gouging" makes the drugs unaffordable to millions of Americans, they said.
"If the prices of these drugs are not substantially reduced, they have the potential to bankrupt the American health care system," Biden and Sanders wrote. "We will not allow that to happen."
Nordisk and Lilly did not immediately respond to an AFP request for comment.
High prices for prescription drugs have been a long-standing problem for American patients, and Democrat Biden has focused on lowering healthcare costs as part of his reelection campaign in November.
The piece in USA Today comes days after Biden's weak performance during a televised presidential debate with Republican Donald Trump sparked sharp concern among Democrats.
E.AbuRizq--SF-PST